Augmentation treatment in major depressive disorder: Focus on aripiprazole

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 5, 2008, Pages 937-948

  Nelson, J Craig ^a   Pikalov, Andrei ^b   Berman, Robert M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antipsychotic; Aripiprazole; Major depression; Mood disorder

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTITHYROID AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; DESIPRAMINE; DEXAMPHETAMINE; ESCITALOPRAM; ESTROGEN; FLUOXETINE; FOLIC ACID; LITHIUM SALT; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; OMEGA 3 FATTY ACID; PAROXETINE; PINDOLOL; PLACEBO; PROGESTERONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ADJUVANT THERAPY; AKATHISIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; FATIGUE; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORBIDITY; MORTALITY; NEUROBIOLOGY; NONHUMAN; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PREVALENCE; PSYCHOLOGICAL ASPECT; RELAPSE; REMISSION; SIDE EFFECT; SOCIAL INTERACTION; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 56849100118     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Abilify. 2007. Bristol-Myers Squibb Company/Otsuka America Pharmaceutical Inc, Aripiprazole (Ability) Prescribing Information. Bristol-Myers Squibb Co and Otsuka America Pharmaceutical, Inc: Princeton, NJ.
2. American Psychiatric Association. 2000. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry, 157:1-45.
3. Andrews G. 2001. Should depression be managed as a chronic disease? BMJ, 322:419-21.
4. Aronson R, Offman HJ, Joffe RT, et al. 1996. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry, 53:842-8.
5. American Psychiatric Association [APA]. 2000. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association.
6. Barbee JG, Conrad EJ, Jamhour NJ. 2004. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry, 16:189-94.
7. Belmaker RH, Agam G. 2008. Major depressive disorder. N Engl J Med, 358:55-68.
8. Berman R, Fava M, Baker RA, et al. 2007a. Metabolic effects of aripiprazole adjunctive therapy in major depressive disorder subpopulations (Studies CN138-139 and CN138-163). Presented at the Annual Meeting of American College of Neuropsychopharmacology, Boca Raton, Florida, USA.
9. Berman RM, Kaplita S, McQuade RD, et al. 2008. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive Disorder (CN138-164). Presented at the Annual Meeting of the American Psychiatric Association, Washington, DC, USA.
10. Berman RM, Marcus RN, Swanink R, et al. 2007b. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry, 68:843-53.
11. Blier P, Gobbi G, Turcotte JE. 2003. A double-blind prolongation study of the combined treatment of depression with mirtazapine and paroxetine. Presented at the Annual Meeting of the New Clinical Drug Evaluation Unit, Boca Raton, Florida, USA.
12. Boulton DW, Balch AH, Royzman K, et al. The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. J Psychopharmacol, In press.
13. Carpenter LL, Yasmin S, Price LH. 2002. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry, 51:183-8.
14. Coppen A and Bailey J. 2000. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord, 60:121-30.
15. Correll CU, Leucht S, Kane JM. 2004. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry, 161:414-25.
16. Corya SA, Andersen SW, Detke HC, et al. 2003. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry, 64:1349-56.
17. Crossley NA, Bauer M. 2007, Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry, 68:935-40.
18. Davis KL, Charney D, Coyle JT, et al. 2002. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA: Lippincott Williams and Wilkins.
19. De Montigny C, Grunberg F, Mayer A, et al. 1981. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry, 138:252-6.
20. Delgado PL, Charney DS, Price LH, et al. 1990. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry, 47:411-18.
21. Dias RS, Kerr-Correa F, Moreno RA, et al. 2006. Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: a double-blind controlled pilot study. Menopause, 13:202-11.
22. Fava M. 2003. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry, 53:649-59.
23. Fava M, Rush AJ, Alpert JE, et al. 2008. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry, 165:342-51.
24. Fava M, Rush AJ, Trivedi MH, et al. 2003. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am, 26:457-94.
25. Fava M, Thase ME, DeBattista C. 2005. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry, 66:85-93.
26. Frasure-Smith N, Lesperance F, Talajic M. 1993. Depression following myocardial infarction. Impact on 6-month survival. JAMA, 270:1819-25.
27. Greenberg PE, Kessler RC, Birnbaum HG, et al. 2003. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry, 64:1465-75.
28. Harpole LH, Williams JW Jr, Olsen MK, et al. 2005. Improving depression outcomes in older adults with comorbid medical illness. Gen Hosp Psychiatry, 27:4-12.
29. Hellerstein DJ, Batchelder S, Hyler S, et al. 2007. Aripiprazole as an adjunctive treatment for refractory unipolar depression. Prog Neuropsychopharmacol Biol Psychiatry, 32:744-50.
30. Jordan S, Koprivica V, Dunn R, et al. 2004. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol, 483:45-53.
31. Katon W, Lin EH, Kroenke K. 2007. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry, 29:147-55.
32. Katon W, Schulberg H. 1992. Epidemiology of depression in primary care. Gen Hosp Psychiatry, 14:237-47.
33. Kessler RC, Berglund P, Demler O, et al. 2003. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289:3095-105.
34. Kupfer DJ. 1991. Long-term treatment of depression. J Clin Psychiatry, 52:28-34.
35. Kupfer DJ. 2005. The pharmacological management of depression. Dialogues Clin Neurosci, 7:191-205.
36. Landen M, Bjorling G, Agren H, et al. 1998. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry, 59:664-8.
37. Lin PY, Su KP. 2007. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry, 68:1056-61.
38. Marcus R, McQuade R, Carson W, et al. 2008. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind placebo-controlled study. J Clin Psychopharmacol, 28:156-65.
39. McGrath PJ, Stewart JW, Fava M, et al. 2006. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry, 163:1531-41.
40. Miller HL, Delgado PL, Salomon RM, et al. 1996. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry, 53:117-28.
41. Moreno FA, Gelenberg AJ, Bachar K, et al. 1997. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry, 58:437-9.
42. Morgan ML, Cook IA, Rapkin AJ, et al. 2005. Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J Clin Psychiatry, 66:774-80.
43. Morris PL, Robinson RG, Andrzejewski P, et al. 1993. Association of depression with 10-year poststroke mortality. Am J Psychiatry, 150:124-9.
44. Moussavi S, Chatterji S, Verdes E, et al. 2007. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet, 370:851-8.
45. Murray CJ, Lopez AD. 1996. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science, 274:740-3.
46. Murray CJ, Lopez AD. 1997. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet, 349:1498-504.
47. Nelson JC. 1987. The use of antipsychotic drugs in the treatment of depression. In: Zohar, J. and Belmaker, R. H. (eds). Treating Resistant Depression. New York: PMA Publishing Corp. p. 131-46.
48. Nelson JC, Kaplita S, Tran QV, et al. 2007. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled analysis (Studies CN138-139 and CN138-163). Presented at the Annual Meeting of the American College of Neuropsychopharmacology, Boca Raton, Florida, USA.
49. Nelson JC, Mazure CM, Jatlow PI, et al. 2004. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry, 55:296-300.
50. Nelson JC, Portera L, Leon AC. 2005. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor? Biol Psychiatry, 57:1535-42.
51. Nierenberg AA, Fava M, Trivedi MH, et al. 2006. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry, 163:1519-530.
52. Nierenberg AA, Papakostas GI, Petersen T, et al. 2003. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol, 23:92-5.
53. Noel PH, Williams JW Jr, Unutzer J, et al. 2004. Depression and comorbid illness in elderly primary care patients: impact on multiple domains of health status and well-being. Ann Fam Med, 2:555-62.
54. Nutt D, Demyttenaere K, Janka Z, et al. 2007. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol, 21:461-71.
55. Nutt DJ. 2006. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry, 67(Suppl 6):3-8.
56. Ostroff RB, Nelson JC. 1999. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry, 60:256-9.
57. Pae CU, Patkar AA, Jun TY, et al. 2007. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress Anxiety, 24:522-6.
58. Papakostas GI. 2006. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol, 16:391-402.
59. Papakostas GI, Petersen T, Denninger JW, et al. 2004. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol, 24:507-11.
60. Papakostas GI, Petersen TJ, Kinrys G, et al. 2005. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry, 66:1326-30.
61. Papakostas GI, Shelton RC, Smith J, et al. 2007a. Augmentation of anti-depressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry, 68:826-31.
62. Papakostas GI, Thase ME, Fava M, et al. 2007b. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry, 62:1217-27.
63. Patkar AA, Masand PS, Pae CU, et al. 2006a. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol, 26:653-6.
64. Patkar AA, Peindl K, Mago R, et al. 2006b. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim Care Companion J Clin Psychiatry, 8:82-7.
65. Paykel ES, Ramana R, Cooper Z, et al. 1995. Residual symptoms after partial remission: an important outcome in depression. Psychol Med, 25:1171-80.
66. Perez V, Soler J, Puigdemont D, et al. 1999. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry, 56:375-9.
67. Raskin A, Schulterbrandt JG, Reatig N, et al. 1970. Differential response to chlorpromazine, imipramine, and placebo. A study of subgroups of hospitalized depressed patients. Arch Gen Psychiatry, 23:164-73.
68. Ressler KJ, Nemeroff CB. 2000. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety, 12(Suppl 1):2-19.
69. Rush AJ. 2007. STAR*D: what have we learned? Am J Psychiatry, 164:201-4.
70. Rush AJ, Fava M, Wisniewski SR, et al. 2004. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials, 25:119-42.
71. Rush AJ, Trivedi MH, Wisniewski SR, et al. 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry, 163:1905-17.
72. Rutherford B, Sneed J, Miyazaki M, et al. 2007. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. Int J Geriatr Psychiatry, 22:986-91.
73. Schule C, Baghai TC, Eser D, et al. 2007. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. World J Biol Psychiatry, 8:112-22.
74. Shapiro DA, Renock S, Arrington E, et al. 2003. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 28:1400-11.
75. Shelton RC, Tollefson GD, Tohen M, et al. 2001. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry, 158:131-4.
76. Simon JS, Nemeroff CB. 2005. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry, 66:1216-20.
77. Solomon DA, Keller MB, Leon AC, et al. 2000. Multiple recurrences of major depressive disorder. Am J Psychiatry, 157:229-33.
78. Stahl M. 2000. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge, UK: Cambridge University Press.
79. Stark AD, Jordan S, Allers KA, et al. 2007. Interaction of the novel antipsychotic aripiprazole with 5-HT(1A) and 5-HT (2A) receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl), 190:373-82.
80. Stewart WF, Ricci JA, Chee E, et al. 2003. Cost of lost productive work time among US workers with depression. JAMA, 289:3135-44.
81. Sullivan PF, Neale MC, Kendler KS. 2000. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry, 157:1552-62.
82. Terao T. 2007. Small doses of aripiprazole augmentation of antidepressants: three case reports. J Clin Psychiatry, 68:843-53.
83. Thase ME. 2002. What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry, 63:95-103.
84. Thase ME, Trivedi MH, Swanink R, et al. 2007. Efficacy of adjunctive aripiprazole in major depressive disorder: a pooled subpopulation analysis (Studies CN138-139 and CN138-163). Presented at the Annual Meeting of the American College of Neuropsychopharmacology, Boca Raton, Florida, USA.
85. Trivedi MH, Fava M, Wisniewski SR, et al. 2006. Medication augmentation after the failure of SSRIs for depression. N Engl J Med, 354:1243-52.
86. Worthington JJ 3rd, Kinrys G, Wygant LE, et al. 2005. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol, 20:9-11.